AstraZeneca’s head of research and development has said the UK drugmaker would consider not submitting its Covid-19 vaccine for approval in the US if it finds it is “banging its head against a brick wall indefinitely” with regulators.
英國制藥商阿斯利康(AstraZeneca)的研發主管表示，如果該公司發現自己在監管機構那里是在“無限期地用頭撞墻”，將考慮不在美國提交新冠病毒疫苗以獲批準。
您已閱讀7%（314字），剩余93%（4018字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。